| Optimer Pharmaceuticals Inc., a development stage company, on Monday said it is planning 5.25 million share in an initial public offering for $12 to $14 per share. The underwriters, led by Piper Jaffray and Jefferies & Company, will have the option to buy 787,500 more shares to cover over-allotments, according to an amended offering document filed with the U.S. Securities and Exchange Commission. The San Diego, California-based is seeking a Nasdaq listing under the symbol "OPTR" |
